Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels

Patent metadata

Field	Value
Publication number	US-10952982-B2
Application number	US-201615577422-A
Country	US
Kind code	B2
Filing date	May 25, 2016
Priority date	May 28, 2015
Publication date	Mar 23, 2021
Grant date	Mar 23, 2021

Abstract

The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of medical conditions (e.g., muscle loss such as sarcopenia, HIV infection and others, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and others) related to reduced levels of glycine, N-acetylcysteine, and/or glutathione.

First claim

The claimed invention is:

1. A method of treating an individual for a medical condition or physical state, the method comprising providing to the individual an effective amount of a composition comprising N-acetylcysteine and a functional derivative of glycine,
wherein the functional derivative of glycine is selected from the group consisting of D-Allylglycine; N-[Bis(methylthio)methylene]glycine methyl ester; Boc-allyl-Gly-OH (dicyclohexylammonium) salt; Boc-D-Chg-OH; Boc-Chg-OH; (R)—N-Boc-(2′-chlorophenyl)glycine; Boc-L-cyclopropylglycine; (R)—N-Boc-4-fluorophenylglycine; Boc-D-propargylglycine; Boc-(S)-3-thienylglycine; Boc-(R)-3-thienylglycine; D-α-Cyclohexylglycine; L-α-Cyclopropylglycine; N-(2-fluorophenyl)-N-(methylsulfonyl) glycine; N-(4-fluorophenyl)-N-(methylsulfonyl)glycine; Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH; N-(2-Furoyl)glycine; L-α-Neopentylglycine; D-Propargylglycine; sarcosine; Z-α-Phosphonoglycine trimethyl ester; and a mixture thereof;
wherein the medical condition or physical state is selected from the group consisting of
muscle loss;
deleterious effects of weightlessness;
osteoporosis;
hypertension;
polycystic ovary syndrome (PCOS);
coronary artery disease;
myocardial damage after stress;
insufficient immunity following vaccination;
ototoxicity;
dizziness; and
a combination thereof;
wherein the composition has at least one formulation selected from the group consisting of (i) the N-acetylcysteine is at least 2 wt. % of the composition and (ii) the functional derivative of glycine is at least 8 wt. % of the composition.

2. The method of claim 1 , wherein the functional derivative of glycine and the N-acetylcysteine are provided to the individual in the same composition.

3. The method of claim 1 , wherein the functional derivative of glycine and the N-acetylcysteine are provided to the individual in different compositions.

4. The method of claim 1 , wherein the functional derivative of glycine and the N-acetylcysteine are provided orally to the individual.

5. A method of treating an individual for a medical condition or physical state, the method comprising providing to the individual an effective amount of a composition comprising N-acetylcysteinylglycine,
wherein the medical condition or physical state is selected from the group consisting of
muscle loss;
deleterious effects of weightlessness;
osteoporosis;
hypertension;
polycystic ovary syndrome (PCOS);
coronary artery disease;
myocardial damage after stress;
insufficient immunity following vaccination;
ototoxicity;
dizziness; and
a combination thereof;
wherein the N-acetylcysteinylglycine is at least 2 wt. % of the composition.

6. The method of claim 5 , wherein the N-acetylcysteinylglycine is at least 8 wt. % of the composition.

Assignees

• Nestec Sa
• Baylor College Medicine
• Nestle Sa

Inventors

• Kirnon Stephen
• Freedland Eric
• Sekhar Rajagopal V

Classifications

• A61K31/155

  Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title

• A61K31/223

  of alpha-aminoacids · CPC title

• A61K31/205

  Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine · CPC title

• A61K31/381

  having five-membered rings · CPC title

• A61K38/21

  Interferons {[IFN]} · CPC title